Research statistics

GH Fragment 176-191 research: publications and trials

What has been published on GH Fragment 176-191: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether GH Fragment 176-191 works or is safe. For what it is and what the studies found, see the GH Fragment 176-191 profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

2

Since 2022

Publications in 2026 so far

1

Through November 15, 2026

Human clinical research

0.0%

0 of 2 classified

Registered clinical trials

0

ClinicalTrials.gov

Randomized controlled trials

0

Publications reporting an RCT in people

Systematic reviews and meta-analyses

0

Preclinical studies

100.0%

0 animal · 2 in vitro · 0 computational

Records that only mention it

1

Not counted above

Status in the library: Research only. Groups: Growth hormone axis.

What to keep in mind

  • No human clinical publication is indexed: everything published so far is preclinical, a review or commentary.
  • Fewer than three randomized controlled trials are indexed.
  • More than 70% of the indexed publications are animal, cell or computational studies.
  • Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.

Publications by year

GH Fragment 176-191 publications by year and evidence

2022: 12026 (to date): 10120222026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearPreclinical (animal, in vitro, computational)
20221
2026 (to date)1

Study types

In vitro study2

Research areas

From MeSH major topics. A paper can be in several areas.

Dermatology1
Endocrinology1
Oncology1

Registered clinical trials

A registration is not a result.

No registered trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

No human trial, systematic review or meta-analysis of GH Fragment 176-191 is indexed.

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.

    Drug design, development and therapy · June 27, 2022 · In vitro study · cited 13 times · open access

    PMID 35783198 · DOI 10.2147/dddt.s367586 · In vitro studies

  2. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.

    The Analyst · July 27, 2026 · In vitro study · cited 0 times

    PMID 42328738 · DOI 10.1039/d6an00455e · In vitro studies

Latest publications

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Fragment 176-191; GH Fragment 176-191; hGH 176-191; HGH Frag; HGH Frag 176-191; HGH Fragment 176-191

((TITLE_ABS:"Fragment 176-191" OR CHEM:"Fragment 176-191" OR TITLE_ABS:"Fragment176-191" OR CHEM:"Fragment176-191") OR (TITLE_ABS:"GH Fragment 176-191" OR CHEM:"GH Fragment 176-191" OR TITLE_ABS:"GH Fragment176-191" OR CHEM:"GH Fragment176-191") OR (TITLE_ABS:"hGH 176-191" OR CHEM:"hGH 176-191" OR TITLE_ABS:"hGH176-191" OR CHEM:"hGH176-191") OR (TITLE_ABS:"HGH Frag" OR CHEM:"HGH Frag") OR (TITLE_ABS:"HGH Frag 176-191" OR CHEM:"HGH Frag 176-191" OR TITLE_ABS:"HGH Frag176-191" OR CHEM:"HGH Frag176-191") OR (TITLE_ABS:"HGH Fragment 176-191" OR CHEM:"HGH Fragment 176-191" OR TITLE_ABS:"HGH Fragment176-191" OR CHEM:"HGH Fragment176-191")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). GH Fragment 176-191 research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/gh-frag-176-191